Status: Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
Participants needed: 128
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Indapta Therapeutics, INC.Updated: Jun 3, 2025Locations: 12
Eligibility criteria
For MM patients: Documented diagnosis of MM requiring systemic therapy and relap... [+3]
Impaired cardiac function or history of clinical significant cardiac disease. [+3]